What Is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It is administered as a once-weekly subcutaneous injection and was first FDA-approved in December 2017 for the treatment of Type 2 diabetes. It is also approved for reducing the risk of major cardiovascular events in adults with Type 2 diabetes and established heart disease.
Ozempic is not FDA-approved for weight loss — that is Wegovy, which uses a higher dose of the same molecule. However, Ozempic has been widely prescribed off-label for weight management since its effectiveness for that purpose became broadly recognized.
How Ozempic Works
Ozempic binds to GLP-1 receptors throughout the body, stimulating insulin release in response to elevated blood sugar, suppressing glucagon, slowing gastric emptying, and reducing appetite through effects on the brain. Its half-life of approximately one week is why it works effectively as a once-weekly injection.
Starting Doses and Titration
Ozempic is typically started at 0.25 mg once weekly for the first four weeks, then increased to 0.5 mg. Based on clinical response and tolerability, the dose may be increased to 1 mg and eventually 2 mg. The gradual titration helps minimize gastrointestinal side effects during adjustment.
Common Side Effects
- Nausea — most common, especially in the first weeks
- Vomiting and diarrhea
- Constipation
- Decreased appetite
- Stomach pain or discomfort
Most side effects are dose-dependent and improve as the body adjusts. Taking Ozempic with a small meal or at bedtime can help reduce nausea.
Ozempic vs. Wegovy: The Key Difference
Both Ozempic and Wegovy contain semaglutide — they are chemically identical. The difference is maximum approved dose and indication. Wegovy goes up to 2.4 mg weekly and is specifically approved for chronic weight management. Ozempic tops out at 2 mg and is approved for diabetes and cardiovascular risk. The higher dose in Wegovy produces greater average weight loss.
August 2026 Update: MDL Litigation & NAION Warning
Ozempic MDL — August 2026: The federal multidistrict litigation (MDL No. 3163) covering alleged GLP-1 side effects continues to grow. As of August 2026, the MDL now includes approximately 3,928 pending cases before Judge Karen Spencer Marston. Lawsuits primarily allege gastroparesis, NAION (non-arteritic anterior ischemic optic neuropathy / vision loss), and failure to warn. European regulators added NAION as a recognized semaglutide side effect in March 2026; as of this writing the U.S. FDA has not issued a formal NAION-specific label change but the prescribing information does include a warning for diabetic retinopathy complications. Separately, Novo Nordisk's Ozempic, Rybelsus, and Wegovy patents are subject to a separate global wave of Hatch-Waxman challenges. None of this affects the drug's availability — patients should discuss any vision symptoms with their physician immediately. Source: Lawsuit Tracker, Motley Rice, August 2026.
September 2026 Update: AI Study Flags Underreported Side Effects
Nature Health Study — September 12, 2026: A University of Pennsylvania research team analyzed more than 400,000 Reddit posts from nearly 70,000 users who discussed semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) over five years. Using AI to surface patterns not captured by clinical trial reporting, the study — published in Nature Health — identified two categories of symptoms that appear underrepresented in official labeling: (1) reproductive symptoms, including menstrual cycle changes (reported by nearly 4% of the sample), and (2) body temperature dysregulation, including chills and hot flashes. The study does not establish causation — it identifies patient-reported signals worth further clinical investigation. Well-known side effects like nausea were also prominent, validating the AI's signal-detection methodology. Researchers note these are signals from spontaneous patient communities, not proof of drug causation, but recommend that clinicians be aware and ask patients directly about these experiences. Source: University of Pennsylvania / Nature Health, September 12, 2026.
Nutrition While on Ozempic
Ozempic significantly reduces appetite, which means the meals you do eat need to work harder. Prioritizing protein at every meal helps preserve muscle mass. Avoiding greasy, high-fat foods reduces nausea intensity. ShedPilot builds your daily meal plan with these principles built in — automatically adjusted to your calorie needs and dietary preferences.